Questcor
Questcor announces commercial availability of Doral and outlines development pipeline
Published in Lab Business Week, July 23rd, 2006
Doral is a nonnarcotic, selective benzodiazepine receptor agonist for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings.
James Fares, Questcor's president and CEO, commented on Questcor's goal to build a high value, low risk pipeline of medically important CNS products.
"With the strong success we are seeing from our efforts to grow Acthar Gel, we are ready to turn to the next stage of our evolution into a leading CNS focused specialty pharmaceutical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2006-07-23)
More Articles from Lab Business Week
- ATS Medical
ATS Medical intends to amend, restate financial documents - Amorcyte
Amorcyte closes $4.2M series A financing - Array BioPharma
Array BioPharma to get $32 million in cash from facilities transactions - Bridge Pharmaceuticals
Patrik Sebastian Jeanmonod appointed vice president finance of Bridge Pharmaceuticals - Corgentech
Corgentech secures $30 million committed equity financing facility - Epeius Biotechnologies
Epeius Biotechnologies awarded $400,000 grant by Lazarex Cancer Foundation for gene trials - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
